亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

来那度胺 医学 耐受性 内科学 养生 美罗华 临床研究阶段 临床终点 中性粒细胞减少症 外科 胃肠病学 多发性骨髓瘤 淋巴瘤 不利影响 临床试验 化疗
作者
Yan Zhang,Wei J. Wang,Jian Li,Daobin Zhou,Wei Yan Zhang,Danqing Zhao,Chong Wei,Lu Zhang,Xinxin Cao
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 6608-6609 被引量:4
标识
DOI:10.1182/blood-2022-165934
摘要

Purpose: We evaluated the tolerability and efficacy of adding lenalidomide to a rituximab and methotrexate combination (R2-MTX) regimen, followed by lenalidomide maintenance as a first-line treatment of patients with primary central nervous system lymphoma (PCNSL). Patients and methods: This multicenter prospective phase Ib/II study, enrolled immunocompetent patients aged 18-75 years with untreated PCNSL. The phase I study increased lenalidomide dose from 15 to 20 to 25 mg. Patients were treated with rituximab 375 mg/m2 and methotrexate 3.5 g/m2 on day 1 and lenalidomide daily for 14 days every 3-week cycle. After 6 cycles of the R2-MTX regimen, responsive patients received lenalidomide maintenance therapy(lenalidomide 25 mg daily for 21 days every 4-week cycle for 2 years).ASCT was optional in eligible patients before lenalidomide maintenance. The primary phase I endpoint was the maximum tolerated dose of lenalidomide. The primary phase II endpoint was the 2-year progression-free survival (PFS). Results: Eleven patients were enrolled in phase Ib of the study. No Dose-limiting toxicities were observed, and the recommend phase II dose of lenalidomide was 25mg. In phase II, 23 patients were treated. The median follow-up period was 14.2 months (range, 8.0-33.4), the estimated 2-year PFS and OS were 61.5%(95% CI 50.7-91.8 ) and 81.7%(95% CI 57.4-92.9), respectively. In the PR2D group, the objective response rate was 92.%, and estimated 2-year PFS and OS were 78.5%(95% CI 50.7-91.8) and 90.4%(95% CI 66.8-97.5). Compared with historical controls in our center, 2-year PFS were significantly improved (P = 0.0088). Hematological toxicities, GI symptoms and infection were the most frequent adverse events, and grade 3/4 toxicities were seen in 62.5% of patients. Quality of life was stabilized during the lenalidomide maintenance phase. Conclusion: R2-MTX regimen supported the integration of lenalidomide to HD-MTX in induction therapy and maintenance as front-line treatment PCNSL patients with good safety, response rate and 2-year PFS. More importantly, the REMLA trial suggested lenalidomide maintenance could be an option instead of WBRT/ASCT consolidation even in younger patients. Randomized trials that incorporate this regimen are needed to determine its efficacy compared with other strategies. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆的应助被吐司采纳,获得10
2秒前
海洋球发布了新的文献求助10
3秒前
dolabmu完成签到 ,获得积分10
5秒前
魔幻雅柔完成签到,获得积分10
6秒前
月亮打烊完成签到 ,获得积分10
9秒前
文静楷瑞完成签到,获得积分10
12秒前
fx完成签到 ,获得积分10
14秒前
14秒前
fantasy的应助被十三采纳,获得10
15秒前
深情安青的应助被outlast采纳,获得10
20秒前
十三完成签到,获得积分10
21秒前
22秒前
26秒前
拼搏问薇完成签到 ,获得积分10
27秒前
28秒前
Abcqqq完成签到 ,获得积分10
28秒前
海洋球完成签到,获得积分10
30秒前
ll完成签到,获得积分20
30秒前
小蘑菇的应助被xx2026采纳,获得10
31秒前
32秒前
kxz完成签到 ,获得积分10
32秒前
33秒前
gale发布了新的文献求助10
36秒前
红墨发布了新的文献求助30
37秒前
39秒前
怕黑的驳完成签到,获得积分10
40秒前
42秒前
43秒前
44秒前
45秒前
吐司发布了新的文献求助10
46秒前
冷静新烟完成签到,获得积分10
46秒前
gale完成签到,获得积分10
49秒前
54秒前
54秒前
TIDUS完成签到,获得积分10
56秒前
独特的念柏完成签到,获得积分10
1分钟前
sadascaqwqw发布了新的文献求助10
1分钟前
36hours完成签到,获得积分10
1分钟前
田様的应助被冷静新烟采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541